Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Caraco Pharmaceutical Laboratories has announced that the FDA has granted final approval for its abbreviated new drug applications for Amitriptyline hydrochloride USP tablets, 10mg, 25mg, 50mg, 75mg, 100mg, and 150mg.
Subscribe to our email newsletter
Caraco’s Amitriptyline hydrochloride is an antidepressant. Its use is indicated to treat symptoms of depression. It is marketed under the brand name of Elavil, a registered trademark of AstraZeneca.
Daniel Movens, CEO of Caraco, said: “We are pleased to gain these approvals from the FDA. Our focus continues to be working towards expanding our product portfolio effectively, including products that are already available generically in the market that potentially can offer additional measurable value.”